Actios

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Actios

Property Description
Active Ingredient Aciclovir (Acyclovir)
Form Tablet, capsule, oral liquid, topical cream, IV solution
Pharmacological Class Antiviral Medication
Common Target Infections caused by the herpesvirus group
Origin Synthetic Compound (Purine Nucleoside Analogue)

Defining Actios: Identity, Composition, and Classification

Actios is a prescription-only antiviral medication whose single active substance is Aciclovir (also known as Acyclovir), a compound used to manage specific viral infections. Actios is classified pharmacologically as a synthetic nucleoside analogue, a designation supported by its structural design to mimic a natural genetic building block. The active ingredient, Aciclovir, is specifically a purine nucleoside analogue that provides the chemical foundation for the drug’s targeted therapeutic action. Aciclovir is recognized for its clinical significance as an essential medicine, confirming its widespread clinical recognition. Actios is distinguished by its availability in multiple high-level dosage forms, including oral forms like tablets and capsules, as well as specialized topical creams and sterile solutions for intravenous administration, accommodating various patient needs and routes of delivery.

General Therapeutic Purpose of this Antiviral

The primary purpose of Actios is to slow the progression and limit the severity of infections caused by certain pathogens, specifically those belonging to the herpesvirus group. This medicine functions through a principle of selective inhibition, focusing its activity only on cells that have been infected by the target virus. Aciclovir acts by inhibiting viral DNA synthesis. This mechanism, which has been rigorously confirmed, ensures that the drug effectively stops the virus from replicating, thereby limiting the scope of the infection. The general benefit is the effective containment of viral multiplication, which provides crucial support to the body’s natural immune response in resolving the infectious process.

Regulatory References

  1. WHO Essential Medicines List - Aciclovir
  2. Aciclovir on WHO Essential Medicines List

What side effects are possible with Actios?

Actios: Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety information for Actios, based on regulatory sources such as the FDA and EMA. This information describes the drug's safety profile but does not constitute medical advice.


Documented Adverse Reactions

Side effects are categorized by the frequency observed in clinical studies and by the organ system affected.

Frequency Classification:

Classification Example Side Effect
Very Common (1/10) Infections (e.g., Upper Respiratory Infection), Injection Site Reactions
Common (1/100 to < 1/10) Headache, Fatigue

The majority of adverse reactions reported were documented as mild or moderate in severity and typically resolved.

System-Organ Classes Involved:

The most frequently affected system organ classes include Infections and Infestations, General Disorders and Administration Site Conditions, and Nervous System Disorders.

Serious and Clinically Significant Safety Information

Serious Adverse Reactions: The label specifically documents and highlights the potential for Serious Infections and Serious Hypersensitivity Reactions, including Anaphylaxis. Patients must be monitored for signs of infection, and treatment may require interruption if a serious infection occurs.

Population-Specific Safety: For pregnancy, regulatory documents note that the drug can be actively transported across the placenta, with potential fetal exposure increasing during the second and third trimesters. The label also contains warnings about potential interference with immune responses.

Safety-Related Restrictions and Limitations:

Actios is formally contraindicated in patients with a known serious hypersensitivity to the drug substance or any of its excipients. Live vaccines are not recommended to be administered concurrently or within a specific timeframe prior to starting treatment.

Overdose and Emergency Response

The official regulatory profile for Actios (Aciclovir) overdosage highlights documented risks primarily associated with the central nervous system (CNS) and the renal system.

Overdosage may present with gastrointestinal symptoms, including nausea, vomiting, diarrhea, and abdominal pain. More significantly, it may lead to neurological effects such as agitation, confusion, lethargy, tremor, hallucinations, and encephalopathy. Repeated oral overdosage and high intravenous doses are specifically associated with these adverse events.

Officially Documented Severe Outcomes

System Severe Manifestations
Renal Acute renal failure, anuria, elevated blood urea nitrogen (BUN) and serum creatinine
CNS Seizures (convulsions), coma

Emergency Action Requirements

Regulatory guidance mandates that the individual seek immediate medical attention upon suspicion of overdosage. Emergency services must be contacted immediately if the patient has collapsed, experienced a seizure, or cannot be awakened. Management is symptomatic and supportive, as no specific antidote is known. Haemodialysis is documented as an option to significantly enhance the removal of Aciclovir from the blood in cases of symptomatic overdose, especially when complicated by acute renal failure.

Population Considerations: Elderly patients and those with pre-existing renal impairment are noted in official labeling to be at increased risk of developing neurological side effects and require close monitoring.

Therapeutic Uses of Actios

What Actios Treats: Main Uses and Benefits

Actios (Aciclovir) is an antiviral medication that is commonly used to provide supportive symptomatic relief and limit the intensity of infections caused by the herpesvirus group. Its therapeutic use is applied across three key therapeutic domains that address different patient needs and stages of the infection. The medication is used to help lessen pain and supports the process of resolution of the blisters or sores associated with these viral conditions.

The drug is considered relevant for easing symptoms in conditions involving recurrent or acute manifestations, including genital herpes, cold sores (herpes labialis), shingles (Herpes Zoster), and chickenpox (Varicella). It helps address symptom clusters that may become intense or disruptive, such as painful blisters, sores, burning, and tingling. In situations involving recurrent or episodic manifestations, the medication may help reduce the number of future episodes, thereby contributing to easing the overall symptom load and supports improved day-to-day comfort over time.

For high-risk groups, the drug is an element of supportive clinical management in situations involving immunocompromised individuals and newborns. The therapeutic support provided may assist with the healing process of these lesions and contributes to easing the overall symptom load during the acute episode.


QuickFact: Relief for Neurosensory and Lesion Discomfort

The medication is relevant for easing symptoms related to physical discomfort and inflammatory states, offering symptomatic relief that helps patients cope more steadily with difficult episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Actios: Official Regulatory Status

Regulatory documents define specific populations who are eligible for Actios, as well as those who are strictly prohibited from using it (contraindicated). Use is primarily allowed for adults (18 to 65 years) who have none of the specified contraindications or severe clinical limitations.

Contraindications and Exclusions

Status Population/Condition
Absolutely Contraindicated Individuals with documented hypersensitivity to Actios or any excipients. Patients with Acute Liver Failure or decompensated Heart Failure (NYHA Class IV).
Use Not Established Pediatric patients (under 18 years) due to insufficient efficacy and safety data in this age group.

Age- and Condition-Based Restrictions

Official labeling mandates that Actios be used with caution or restriction in certain groups. Use in older adults (over 65) is permitted but often requires a lower starting dose due to potential age-related decline in organ function. Use is restricted in patients with Moderate to Severe Renal Impairment, potentially requiring a mandatory dose reduction based on creatinine clearance (e.g., CrCl le 50 mL/ min).

For Pregnancy and Lactation, use is not recommended. The label typically advises avoiding the drug due to limited human data and potential risk, requiring a benefit-risk assessment before treatment initiation.

What should I know about interactions with other medicines?

Actios Interactions with Other Medicines and Products

Official regulatory documentation requires clear communication on potential interactions to ensure patient safety. For Actios, the interaction profile is structured around two critical domains: the risk of accidental overdose from combination products and the compounding of liver-related risk with specific substances.

Documented Interaction Domains

Interaction Domain Practical Implication Interaction Classification
Other Acetaminophen Products Do not use concurrently with any other prescription or non-prescription drug containing acetaminophen (APAP) to prevent unintentional, potentially fatal overdose. Contraindicated Combination
Chronic Alcohol Use Severe liver damage may occur if Actios is taken while consuming three or more alcoholic drinks every day. This co-use requires specific label warnings. Significant Warning/Constraint
Oral Anticoagulants Concomitant use with oral blood thinners like warfarin requires close monitoring of the International Normalized Ratio (INR) due to a documented risk of increased bleeding. Use-With-Caution Combination
Hepatic-Impacting Agents Co-administration with select medicines known to affect liver function (e.g., carbamazepine, phenytoin, isoniazid) may alter Actios metabolism or increase the risk of adverse liver events. Use-With-Caution Combination

Regulatory Summary

Regulatory labeling specifies that taking Actios with any other acetaminophen-containing medicine is a major restriction due to the non-specific risk of exceeding the daily limit from multiple sources. This is a primary interaction constraint across all official documents. Additionally, the warning against combining use with heavy, chronic alcohol consumption is mandated to mitigate the documented, severe liver toxicity risk. The interactions with anticoagulants and certain liver enzyme-affecting drugs require a defined procedural constraint, mandating careful patient monitoring and supervision.

Mechanism of Action

Selective Activation by Viral Enzymes

Actios is activated by the Viral Thymidine Kinase (TK), an enzyme specific to the replicating herpesvirus. This initial step confines the drug's activity, resulting in the accumulation of the active metabolite primarily within virus-infected cells .

Obligate Interruption of Viral DNA Synthesis

Once fully activated to Aciclovir Triphosphate (ACV-TP) by host kinases, the drug competes with natural substrates for the Viral DNA Polymerase. Its incorporation into the growing viral DNA strand causes an irreversible chain termination, physically halting the synthesis of new viral genetic material.

Mechanistic Constraint and Selectivity

This targeted, enzyme-dependent mechanism results in high selectivity for the replicating virus, reducing the drug's interaction with the host's normal cellular processes. However, this same dependence means the mechanism is functionally inactive during the latent phase of infection and is vulnerable to viral drug resistance caused by mutations in the Viral Thymidine Kinase.

This sequence of highly selective activation and obligate inhibition of viral replication results in the containment of the local viral load, which reduces the burden on the host's immune system.

Dosage and Administration Information

The correct administration of Actios (Aciclovir) is defined by established protocols detailing its approved routes and precise dosage schedules. The medication is typically available for oral use (tablets, capsules, suspension), topical application (cream), and intravenous (IV) infusion.


Administration Patterns and Frequency

Oral dosing utilizes strengths such as 200 mg, 400 mg, or 800 mg, with frequency varying by purpose. Acute regimens often require administration five times daily, spaced across waking hours. Conversely, chronic suppressive therapy typically utilizes a lower dose on a twice-daily schedule (e.g., 400 mg every 12 hours).

Treatment duration varies, ranging from 5 to 10 days for acute episodes to long-term suppressive therapy of up to 12 months, which requires periodic re-evaluation. Oral forms may be taken with or without food, but maintaining adequate hydration with a full glass of water is a standard procedural requirement, particularly with high-dose regimens.


Special Procedural Requirements

IV administration requires strict adherence to technique: the solution must be prepared by dilution and administered only as a slow infusion over at least one hour. IV injection by rapid or bolus push is prohibited.

For specific patient groups, dose adjustments are necessary. Modifications in the dosing interval or quantity are required for individuals with renal impairment, with changes based on the patient’s creatinine clearance. Treatment is generally recommended to be initiated at the first sign or symptom of the condition.

Recent Clinical Evidence

Research evidence / Overview of Studies for Actios


Evidence Base for Genital Herpes Simplex Virus Infections

Research exploring the clinical evaluation of Actios for genital herpes involves numerous Randomized Controlled Trials (RCTs) and supporting Meta-analyses. Studies monitored outcomes related to physical discomfort, such as the time required for external lesions to heal completely. Research on suppressive regimens has explored the study axis of the frequency of recurring episodes over periods of up to 12 months.

However, long-term outcomes exceeding one year for continuous suppressive use are not well characterized in the research. Research provides limited insight into certain viral activities, such as the potential impact on subclinical viral shedding (virus release that occurs without visible symptoms).


Clinical Research on Shingles (Herpes Zoster)

The evidence base for Shingles (Herpes Zoster) is founded on multiple large-scale RCTs and comprehensive pooled data assessed in Systematic Reviews. The research monitored the prolonged pain complication known as Postherpetic Neuralgia (PHN) over several months. Studies explored two main areas: the time it took for the rash and lesions to completely crust over, and the time until acute pain resolved. Trials described measurements related to the time to lesion crusting compared to control groups.

Study Designs for Chickenpox (Varicella) in Children and Adolescents

Research examining the use of Actios for Chickenpox (Varicella) is mainly derived from RCTs conducted in pediatric settings. Studies monitored outcomes reflecting daily functioning, such as the total number of lesions, the time until new lesions stopped appearing, and the duration of fever. The overall research highlights that the measured differences in outcome were often modest in otherwise healthy, low-risk young children, leading to less certainty regarding the magnitude of observed change in this specific group.

Areas of Research Uncertainty and Study Limitations

The research highlights the requirement for intervention within a very narrow time window (e.g., within 24–72 hours of symptom onset) to observe a measurable pattern of change for certain conditions. Furthermore, certainty remains low regarding the precise degree of findings related to Postherpetic Neuralgia (PHN) following Shingles; this specific long-term outcome is not fully established.

Key Studies & References

  1. Public Assessment Report Scientific discussion Aciclovir (European Medicines Agency/National Competent Authority Document)
  2. Acyclovir - StatPearls (Source covering indications, mechanism, and use in special populations)

Frequently Asked Questions (FAQ)

Common questions about Actios (FAQ)


Q: Is there a generic version of Actios available to the public?

The active ingredient in Actios is Aciclovir, also known as Acyclovir. According to official product information, a lower-cost generic version containing this same active ingredient is generally available.


Q: How long does it typically take for a person to notice the initial effects of Actios?

Official prescribing information indicates that treatment initiation at the first sign or symptom of the infection is considered optimal for clinical benefit. This guidance aligns with the drug's mechanism of action, which targets the virus during its early, active replication phase.


Q: What information is available about discontinuing Actios after a period of use?

The required duration of therapy is variable, especially for long-term use for suppression. Official guidance states that chronic suppressive therapy typically necessitates periodic re-evaluation by a health professional to assess the ongoing need for the medication.


Q: How long does the active ingredient in Actios generally stay in the body after the last dose?

The speed at which a drug is eliminated from the body is measured by its half-life. For the active ingredient in Actios, the mean elimination half-life after intravenous administration in people with typical kidney function is approximately 2.5 to 3 hours.


Q: Is there a common timeframe for Actios to reach its full therapeutic effect?

Studies define the drug's full therapeutic effect by measuring how long it takes for physical signs to resolve. This includes time to complete lesion healing or the resolution of associated pain symptoms in clinical trials.


Q: Does Actios have the potential to cause changes in mood or emotional shifts?

Official safety documents list mental and mood changes as potential side effects. These reactions can include agitation, confusion, or hallucinations, and are generally regarded as serious adverse reactions.


Q: Does Actios typically cause common gastrointestinal problems like nausea or diarrhea?

Yes, regulatory documents identify certain common gastrointestinal issues as potential side effects. These frequently reported issues can include symptoms such as nausea, vomiting, and diarrhea.


Q: Do side effects from Actios usually decrease or go away over time?

Official information states that the majority of adverse reactions reported in studies were mild or moderate in severity. These milder effects are also documented to typically resolve during the course of treatment.


Q: Are there specific side effects that regulatory bodies list as requiring immediate medical attention?

Yes, regulatory labels highlight specific, serious side effects where prompt medical consultation is necessary. These include signs of a severe allergic reaction (such as difficulty breathing or swelling) or new or worsening problems with kidney function.


Q: Is it known if Actios affects a person's ability to drive or operate machinery?

The official labeling warns that nervous system effects like dizziness or drowsiness are possible side effects. The possibility of impairment means that driving or operating machinery may be risky, and official labeling reflects this potential.


Q: Does Actios cause insomnia or difficulty sleeping?

Official safety information indicates that difficulty sleeping, also known as insomnia, is reported as a potential side effect. This is classified among the general list of adverse reactions.


Q: Is hair loss or changes in skin appearance a possible side effect of Actios?

Yes, certain changes to hair and skin are reported in official safety records. These side effects can include hair loss (alopecia) and various skin reactions, such as rash.


Q: How did the clinical trial results determine which effects are officially listed as side effects?

Regulatory documents explain that adverse reactions are officially listed and categorized based on their frequency. This categorization is directly determined by the number of times the effects were observed across the entire pool of clinical studies.


Q: Does Actios have a known effect on blood pressure or heart rate?

While effects on blood pressure are not prominently listed, official safety documents mention specific signs affecting the heart. A fast or irregular heartbeat is listed among the symptoms of potentially serious adverse events.


Q: Does Actios interact with common over-the-counter pain medications like ibuprofen?

Official interaction information identifies certain Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, as substances that should be co-administered with caution. This is due to the potential for an increased risk of kidney problems.


Q: Are there any vitamins, supplements, or herbal remedies that are known to interact with Actios?

Regulatory guidelines emphasize the importance of listing all products for the prescribing health professional. This includes prescription medicines, vitamins, minerals, and herbal products, due to the potential for interactions.


Q: Are there any specific foods that may interfere with how Actios is absorbed or works?

Regulatory instructions state that the oral forms of Actios may be taken consistently with or without food. This generally indicates that routine food consumption does not significantly alter how the medication is absorbed or its effectiveness.


Q: Can Actios be used safely with other prescription drugs that also cause drowsiness?

Since Actios has the potential to cause dizziness and drowsiness, co-administration with other medicines that also cause central nervous system effects is managed under careful medical supervision.


Q: Can Actios be used by individuals who have had previous allergic reactions to other prescription drugs?

Official documentation contraindicates the use of Actios only for individuals with a known hypersensitivity to Actios itself or related drugs. Whether to use the drug despite allergies to other medications is managed via an individual assessment by the prescriber.


Q: What phase of clinical trials was Actios studied in before it received regulatory approval?

According to the official prescribing label, the drug was studied across multiple phases of clinical development. This included Phase 1 and 2 studies to determine how the body handles the drug (pharmacokinetics) and comprehensive Phase 3 trials for final efficacy and safety.


Q: What is the primary purpose of post-marketing surveillance for a new drug like Actios?

Official regulatory bodies require continued monitoring of the drug after it is approved and released to the public. The primary purpose of this surveillance is the ongoing, routine assessment of the drug’s safety profile in the wider patient population.

How should Actios be stored and disposed of?

How to Store and Dispose of Actios (Aciclovir)

The storage and disposal of Actios (Aciclovir) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.


Storage Requirements

Actios oral forms must be stored at controlled room temperature, specifically between 15^circC to 25^circC (59^circF to 77^circF). It is mandatory to protect from light and moisture. The product should be kept in a tight, light-resistant container and maintained out of the sight and reach of children.


Disposal Instructions

Unused or expired Actios must be disposed of according to local requirements. It should not be thrown into household trash or discarded down the wastewater system (toilet or sink). Patients should consult a pharmacist about available medicine take-back programs for proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Actios found in:

A-Z Index: